Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 5/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Upidosin SCHEMBL29387625 | 1.00 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL8875338 | 0.98 | HTR1A (0.97) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| Upidosin SCHEMBL8875369 | 0.98 | HTR1A (0.97) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| Upidosin SCHEMBL8875378 | 0.98 | HTR1A (0.97) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL8875781 | 0.98 | HTR1A (0.95) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| Upidosin SCHEMBL8907074 | 0.97 | HTR1A (0.94) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| Upidosin SCHEMBL8908584 | 0.96 | HTR1A (0.93) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL8875547 | 0.95 | HTR1A (0.91) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL8876438 | 0.95 | HTR1A (0.91) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL8875563 | 0.95 | HTR1A (0.91) | HTR1AADRA1DADRA1AADRA1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5605896-A | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-02-25 | — | — | US | claimed |
| US-5403842-A | Adrenergic blocking and antiserotonine agents; urogenital disorders including spasms of the urethral tract and prostrate problems | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-04-04 | — | — | US | claimed |
| WO-1993017007-A1 | HETEROBICYCLIC COMPOUNDS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 1993-09-02 | — | — | WO | claimed |
| EP-0558245-A1 | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1993-09-01 | — | — | EP | claimed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | UNIAO BRASILIENSE DE EDUCACAO E CULTURA-UBEC (BR) | 2007-09-20 | — | — | US | disclosed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6410554-B1 | ADRENERGIC ANTAGONIST | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| EP-0669932-A4 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE. | SMITHKLINE BEECHAM CORP (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0673251-A1 | 17 SUBSTITUTED ACYL-3-CARBOXY 3,5-DIENE STEROIDALS AS 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0669932-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995021185-A1 | ACYL 3-CARBOXY AROMATIC A RING STEROID AS 5-ALPHA REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-08-10 | — | — | WO | disclosed |
| US-5403842-A | Adrenergic blocking and antiserotonine agents; urogenital disorders including spasms of the urethral tract and prostrate problems | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-04-04 | — | — | US | disclosed |
| WO-1995005821-A1 | DI- AND TETRA-HYDROBENZO[F]QUINOLIN-3-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-02 | — | — | WO | disclosed |
| WO-1994011386-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011004-A1 | 17 SUBSTITUTED ACYL-3-CARBOXY 3,5-DIENE STEROIDALS AS 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | HTR1A 2390/4885ADRA1D 996/4885ADRA1A 1191/4885 |
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | ADRA1D, ADRB1, ADRA1A | HTR1A 21/4885ADRA1D 1/4885ADRA1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.